From GlobeNewswire: 2024-04-12 08:00:00

Notable Labs, Ltd. (Nasdaq: NTBL) reported financial results for 2023, with $11.8 million in cash as of December 31, 2023, and $8.2 million as of April 1, 2024. The company aims to enhance its lead product candidate, volasertib, for r/r AML in a Phase 2 trial by utilizing its PPMP platform to predict patient responses.

Notable Labs, Ltd. plans to initiate a Phase 2 trial for volasertib in the coming months, incorporating learnings to enhance patient responses. With strategic partnerships and breakthrough designations, Notable aims to fast-track volasertib’s clinical development and improve patient outcomes. The company’s unique Predictive Precision Medicines Platform aims to revolutionize precision medicine in cancer treatment.

Total net revenue for Notable Labs, Ltd. in 2023 was $0.3 million, with research and development expenses at $4.7 million. General and administrative expenses were $10.1 million in 2023, reflecting increased costs associated with being a public company. The company’s net loss for 2023 decreased to $(11.3) million, or $(3.41) per share, versus $(14.4) million in 2022.



Read more at GlobeNewswire:: Notable Labs Reports 2023 Financial Results and Provides a